New Concepts of Biomarkers and Clinical Outcomes for Therapeutic Cancer Vaccines in Clinical Trials

References

• Wolchok JD, Hoos A, O’Day S et al. Guidance for the evaluation of immune therapy activity in solid tumours: immune-related response criteria. Clin. Cancer Res. 15(23), 7412–7420 (2009).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunol. 25(2), 97–138 (2002).
   Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949–1955 (2011).
   PubMed Web of Science ®Google Scholar
• Balermpas P, Michel Y, Wangenblast J et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer 110(2), 501–509 (2014).
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin. Oncol. 29, 610–618 (2011).
   PubMed Web of Science ®Google Scholar
• West NR, Kost SE, Martin SD et al. Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 108, 155–162 (2013).
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Bol K, Schreibelt G et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res. 72(23), 6102–6110 (2012).
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 28, 3894–3903 (2000).
   Google Scholar
• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer. Cancer 115, 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized Phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 62, 137–147 (2013).
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. 13(6), 401–407 (2003).
   PubMed Web of Science ®Google Scholar
• Morton DL, Foshag LJ, Hoon DS et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216(4), 463–482 (1992).
   PubMed Web of Science ®Google Scholar
• Koc ON, Redfern C, Wiernik PH et al. A Phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J. Immunother. 33, 178–184 (2010).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/Bbcille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organization for Research and Treatment of Cancer 08971–08971B; Silva Study). J. Clin. Oncol. 23, 6854–6864 (2005).
   PubMed Web of Science ®Google Scholar
• Brett BT, Smith SC, Bouvier CV et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20, 4225–4231 (2002).
   PubMed Web of Science ®Google Scholar
• Gilliam AD, Broome P, Topuzov EG et al. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 41(3), 374–379 (2012).
   PubMed Web of Science ®Google Scholar
• Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42, 303–309 (1996).
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC, Schuchter LM et al. Autologous hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15, 2359–2370 (1997).
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22, 403–415 (2004).
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717–4724 (2004).
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253(2), 328–335 (2011).
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 1254–1261 (2012).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663–674 (2010).
   PubMed Web of Science ®Google Scholar
• Vergati M, Cereda V, Gulley JL et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post- vaccination. Cancer Immunol. Immunother. 60(2), 197–206 (2011).
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27, 4685–4692 (2009).
   PubMed Web of Science ®Google Scholar
• Amin A, Benavides LC, Holmes JP et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol. Immunother. 57, 1817–1825 (2008).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Tsang KY et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol. Res. 2, 133–141 (2014).
   PubMed Web of Science ®Google Scholar
• Streitz M, Miloud T, Kapinsky M et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Trans. Res. 2(1), 17 (2013).
   Google Scholar
• Tjin EP, Konijnenberg D, Krebbers G et al. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res. 17(17), 5736–5747 (2011).
   PubMed Web of Science ®Google Scholar
• Benteyn D, Van Nuffel AM, Wilgenhof S et al. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed. Res. Int. 2013, 976383 (2013).
   PubMed Web of Science ®Google Scholar
• Bonchill A, Van Nuffel AM, Corthals J et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res. 15, 3366–3375 (2009).
   PubMed Web of Science ®Google Scholar
• Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+CD4+CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta1. J. Immunol. 182(1), 111–120 (2009).
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1 (2012).
   PubMed Web of Science ®Google Scholar